grant
Molecular features promoting sensitivity to LSD1i in castration-resistant prostate cancer
Organization JOHNS HOPKINS UNIVERSITYLocation BALTIMORE, UNITED STATESPosted 1 Mar 2024Deadline 28 Feb 2029
NIHUS FederalResearch GrantFY2025ACSL1ACSL1 GeneAOF2ASCL1ASCL1 geneASCL1 proteinASH1Achaete-Scute Complex Homolog-Like 1 ProteinAchaete-Scute Complex-Like 1 ProteinAchaete-Scute Homolog 1 ProteinAndrogen ReceptorBioavailabilityBiologic ModelsBiological AvailabilityBiological ModelsCancer PatientCastrationCell BodyCellsClinicalClinical TrialsCognitive DiscriminationCombined Modality TherapyDataDevelopmentDiscriminationDiseaseDisorderDoseDrug CombinationsDrug KineticsDrug resistanceDrugsEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessFDA approvedFrequenciesFutureGene TranscriptionGeneticGenetic TranscriptionGoalsHASH1HASH1 proteinHeterogeneityHormonalINSM1In VitroInnovative TherapyKDM1AKDM1A geneLSD1LesionLysine-Specific Demethylase 1Lysine-Specific Demethylase 1AMASH 1 proteinMASH1MASH1 proteinMalignant neoplasm of prostateMalignant prostatic tumorMammalian Achaete-Scute Homolog 1MediatorMedicationMixed NeoplasmMixed TumorModel SystemModelingMolecularMultimodal TherapyMultimodal TreatmentNeuroendocrine Prostate CancerNew AgentsOralOrganoidsPDX modelPathologicPathway interactionsPatient SelectionPatient derived xenograftPatientsPharmaceutical PreparationsPharmacogenomicsPharmacokineticsPhenotypePhysiologic AvailabilityPre-Clinical ModelPreclinical ModelsPredispositionPrevalencePrognosisProliferatingProstate CAProstate CA therapyProstate CancerProstate Cancer therapyProstate malignancyRNA ExpressionResistanceSafetySpecificitySurgical CastrationSusceptibilityTechnologyTestingTherapeuticTranscriptionVariantVariationWorkXtandiabirateroneandrogen independent prostate cancerandrogen indifferent prostate cancerandrogen insensitive prostate cancerandrogen resistance in prostate cancerandrogen resistant prostate cancerbiomarker drivencancer sub-typescancer subtypescastration resistant CaPcastration resistant PCacastration resistant prostate cancerclinical developmentcohortcombatcombination therapycombined modality treatmentcombined treatmentdevelopmentaldrug resistantdrug/agenteffective therapyeffective treatmentenzalutamideepigeneticallygenome scalegenome-widegenomewidehormone refractory prostate cancerin vivoinhibitorinnovateinnovationinnovativeinsulinoma associated 1menmulti-modal therapymulti-modal treatmentnovelpathwaypatient derived xenograft modelprecision medicineprecision-based medicinepredictive biological markerpredictive biomarkerspredictive markerpredictive molecular biomarkerprogramsprostate cancer cellprostate cancer resistant to androgenprostate cancer treatmentprostate tumor cellrational designresistance mechanismresistance to Drugresistance to therapyresistantresistant mechanismresistant to Drugresistant to therapyresponseresponse biomarkerresponse markersscreeningscreeningsstandard of caresynergismsynthetic lethal interactionsynthetic lethalitytargeted agenttargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic resistancetherapy resistanttreatment resistancetumor
Description preview
Prostate cancer (PCa) remains an incurable disease once progression to the metastatic castration-resistant
(mCRPC) state occurs; killing >30,000 U.S. men/yr. Unfortunately, each of the FDA-approved agents for mCRPC
produces only modest increases in overall survival followed by the emergence of a resistant and more aggressive
phenotype. Thus, there…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click